MedPath

Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Phase 3
Completed
Conditions
Apatinib
Interventions
Drug: Apatinib
Drug: Oxaliplatin
Drug: 5-fluorouracil
First Posted Date
2017-12-07
Last Posted Date
2023-02-14
Lead Sponsor
Huashan Hospital
Target Recruit Count
63
Registration Number
NCT03365765
Locations
🇨🇳

Huashan Hospital Affiliated to Fudan University, Shanghai, China

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3
Active, not recruiting
Conditions
Head and Neck Cancer
Interventions
Drug: Pembrolizumab
Drug: Cetuximab
Drug: Epacadostat
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-Fluorouracil
First Posted Date
2017-11-30
Last Posted Date
2024-06-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
89
Registration Number
NCT03358472
Locations
🇺🇸

U of Kansas Cancer Center, Westwood, Kansas, United States

🇦🇺

Royal Brisbane & Women s Hospital, Herston, Queensland, Australia

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 70 locations

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Phase 2
Conditions
Breast Cancer
Pathological Complete Response
Neoadjuvant Chemotherapy
Interventions
Drug: Epirubicin
Drug: Fluorouracil
Drug: Docetaxel
Drug: Cyclophosphamide
First Posted Date
2017-11-21
Last Posted Date
2017-11-21
Lead Sponsor
Zhiyong Yu
Target Recruit Count
200
Registration Number
NCT03349177

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Phase 3
Active, not recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: Docetaxel
Radiation: radiotherapy
Drug: Cisplatin
Drug: Fluorouracil
First Posted Date
2017-11-14
Last Posted Date
2024-03-07
Lead Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Target Recruit Count
256
Registration Number
NCT03340896
Locations
🇫🇷

Centre Jean Bernard, Le Mans, France

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3
Withdrawn
Conditions
Head and Neck Cancer
Interventions
Drug: Carboplatin
Drug: Nivolumab
Drug: Placebo
Drug: Epacadostat
Drug: Cetuximab
Drug: Cisplatin
Drug: 5-Fluorouracil
First Posted Date
2017-11-14
Last Posted Date
2019-12-20
Lead Sponsor
Incyte Corporation
Registration Number
NCT03342352

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Advanced Pancreatic Cancer
Interventions
Drug: Nab-paclitaxel
Biological: Cabiralizumab
Biological: Nivolumab
Drug: Onivyde
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Gemcitabine
Drug: Leucovorin
Drug: Irinotecan Hydrochloride
First Posted Date
2017-11-08
Last Posted Date
2024-07-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
205
Registration Number
NCT03336216
Locations
🇺🇸

Local Institution - 0006, Philadelphia, Pennsylvania, United States

🇺🇸

Local Institution - 0007, Los Angeles, California, United States

🇺🇸

Dana Farber Cancer Institute., Boston, Massachusetts, United States

and more 38 locations

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Biliary Tract Carcinoma
Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7
Stage IVB Colorectal Cancer AJCC v7
Metastatic Gastroesophageal Junction Adenocarcinoma
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Metastatic Colorectal Carcinoma
Metastatic Malignant Digestive System Neoplasm
Interventions
Drug: Fluorouracil
Drug: Irinotecan Sucrosofate
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Rucaparib
First Posted Date
2017-11-08
Last Posted Date
2024-05-17
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
18
Registration Number
NCT03337087
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

First Posted Date
2017-11-01
Last Posted Date
2024-12-12
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
6
Registration Number
NCT03329248
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1
Completed
Conditions
Biliary Tract Cancer (BTC)
Colorectal Cancer (CRC)
Endometrial Cancer
Gastroesophageal Cancer (GC)
Ovarian Cancer
Solid Tumors
Interventions
Drug: INCB001158
Drug: Oxaliplatin
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Cisplatin
Drug: Leucovorin
Drug: 5-Fluorouracil
First Posted Date
2017-10-19
Last Posted Date
2023-12-07
Lead Sponsor
Incyte Corporation
Target Recruit Count
149
Registration Number
NCT03314935
Locations
🇺🇸

Northwest Georgia Oncology Centers, Marietta, Georgia, United States

🇺🇸

USA Mitchell Cancer Center, Mobile, Alabama, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

and more 7 locations

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Phase 1
Withdrawn
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Squamous Cell Carcinoma of the Esophagus
Interventions
Drug: Monalizumab
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Other: Metabolic
Procedure: Surgery
First Posted Date
2017-10-12
Last Posted Date
2017-12-19
Lead Sponsor
Jules Bordet Institute
Registration Number
NCT03307941
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy